Navigation Links
Nutraceutical Reports 2008 Fiscal Year End Results
Date:11/20/2008

2,235 4,202 18,960 20,923 Provision for income taxes 708 1,597 7,017 7,951 Net income $1,527 $2,605 $11,943 $12,972 Net income per common share Basic $0.14 $0.23 $1.09 $1.17 Diluted 0.14 0.23 1.07 1.15 Weighted average common shares outstanding Basic 10,846,018 11,136,702 10,993,505 11,054,828 Diluted 10,966,785 11,307,910 11,127,634 11,253,283 NUTRACEUTICAL INTERNATIONAL CORPORATION ADJUSTED EBITDA SCHEDULE (unaudited; dollars in thousands) Three months Twelve months ended ended September 30, September 30, 2008 2007 2008 2007 Net income $1,527 $2,605 $11,943 $12,972 Provision for income taxes 708 1,597 7,017 7,951 Interest and other (income)/expense, net (1) 262 443 1,270 1,257 Depreciation and amortization 1,603 1,292 5,859 4,793 Impairment of goodwill and intangible asset (2) 2,875 450 2,875 450 Adjusted EBITDA $6,975 $6,387 $28,964 $27,423 (1) Includes amortization of deferred financing fees. (2) A non-cash goodwill impairment charge of $2,875 related to the company's health food stores was recorded for the three months and twelve months ended September 30, 2008. A non-cash intangible asset impairment charge of $450 related to the re-b
'/>"/>
SOURCE Nutraceutical International Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as Lifestyle Support for a Fast-Paced World
2. Nutraceutical to Present at Canaccord Adams Healthy Living Conference
3. Nutraceuticals could prevent diabetes
4. Nutraceutical Reports Q3 Results
5. Dermatologists In Denial: Controversial New Chocolate Nutraceutical Claims to be Good for Your Skin
6. Photos: For the First Time Researchers Show Reversal of an Aging Marker in the Human Retina Correlated with Visual Improvement Using a Nutraceutical Matrix (Longevinex(R))
7. Berkeley Premium Nutraceuticals Pushes Forward
8. Direct Response TV Course on Nutraceutical/Cosmeceutical Products to Premiere in New York City
9. Nellson Nutraceutical Names New Directors and Interim Chief Executive Officer
10. Nutraceutical Reports Fiscal 2008 Q1 Results
11. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...udy released this week showing that a growing numb...c diseases shines a much-needed spotlight on the n...at focuses on primary and secondary prevention, ac... disease prevention. , , (Logo: http://www...., , The study, conducted by Social & Scient...
(Date:1/8/2009)...chle at his confirmation hearing to be the next Se...SHINGTON, Jan. 8 Bipart...ator Tom Daschle, nominee for Department of Health...ellow BPC founder and friend Senator Bob Dole at h...vened by the Senate Health, Education, Labor, and ...
(Date:1/8/2009)...earch Hospital have demonstrated a more effective ...nza. They found that the antibiotics clindamycin a... their protein synthesis, are more effective than ...tam" antibiotic ampicillin, which causes the bacte...ant because pneumonia, rather than the influenza i...
(Date:1/8/2009)...re-FirstCall/ -- Medivation, Inc.,(Nasdaq: MDVN...t and chief,executive officer, will present at th...n Wednesday, January 14, at 10:00 a.m. Pacific Tim...o. , Dr. Hung will provide an overview of M...or Dimebon for Alzheimer,s and Huntington,s diseas...
Breaking Medicine News(10 mins):Health News:U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 3Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 4Health News:Study finds more effective treatment for pneumonia following influenza 2Health News:Study finds more effective treatment for pneumonia following influenza 3Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2
...ine has been shrouded in controversy. Now, Britain...alled for an end to the raging //debates over this...public that warns of a threat to young lives by fo...They have appealed to the politicians, healthcare ...
...lison, a University of Alabama biostatistician has...ons for obesity. //He was assisted in this venture...da and Italy. The researchers looked at more than... besides exercise and diet. They found that the fo...
... is on the rise in New Zealand. Hence Pharmac deci...se who have serious fluctuations in blood sugar le...r Lantus at a subsidized rate from July 1. Murra... the Diabetes New Zealand said that they have work...
...rays of women with high-risk genes could increase ...archers led by David Goldgar // at the Internation...d 1,600 women. He found that women with BRCA1 and ... mutations who had undergone a chest X-ray were 54...
Other Medicine News:
(Date:1/3/2009)... , , , , ROSEMONT, Ill., Jan. 2...ging (MRI) is a growing technology providing an in...the evaluation of back pain according to an articl...American Academy of Orthopaedic Surgeons ( http://...ext several years, additional technical developmen...
(Date:12/29/2008)...BETHESDA, Md., Dec. 29 ...an Research Protection was announced today by Dr. ... Health Improvement Institute. , , The winner ... M.D. Anderson Cancer Center -- for its best pr...This program provides for 1) enhanced human subjec...
(Date:12/27/2008)... SAN DIMAS, Calif., Dec. 27 Acc...ers are best advised to consume modest doses of,r...as typically provided in 3,to 5 glasses of aged, ...(Photo: http://www.newscom.com/cgi-bin/prnh/2008...ws mega-dose resveratrol alone fails to prolong,t...
(Date:12/17/2008)...ificant milestone met in development and validatio... ASHLAND, Mass., Dec. 17 MatTek C...ic Advisory Committee (ESAC) endorsed the scientif...n Test (SIT) at its November meeting. ESAC conclu...ccuracy and reliability for the prediction of skin...
Breaking Medicine Technology:MRI Emerges As Vital Resource in Treatment of Back Pain 2MRI Emerges As Vital Resource in Treatment of Back Pain 32008 Human Research Protection Award Recipients Announced 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 3EpiDerm's Skin Irritation Test Fully Validated in European Union 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2088 1Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2088 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2088 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2088 4Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2088 5MIT solves gravity defying bird beak mystery 3337 1MIT solves gravity defying bird beak mystery 3337 2MIT solves gravity defying bird beak mystery 3337 3UC San Diego nanostructures will raise thin film solar cell efficiency 5463 1UC San Diego nanostructures will raise thin film solar cell efficiency 5463 2Celebrex shows benefit in first of its kind lung cancer chemoprevention trial 19563 1Celebrex shows benefit in first of its kind lung cancer chemoprevention trial 19563 2Celebrex shows benefit in first of its kind lung cancer chemoprevention trial 19563 3
...abasis Therapeutics,Inc. (Nasdaq:MBRX), a biophar...opment and commercialization of novel drugs for th...lying unique,capabilities for targeting the liver ...rs were presented at the Endocrine Society,s,89th ...rovide data on MB07811, the Company,s,liver-target...
...able to two widely used diabetes medicines , , ...n 33,000 type 2 diabetes patients in a real-world,... the incidence of,hospitaliations for heart attack...rization for patients on Avandia is the,same as ...ere,released in a paper titled “Coronary Hea...
Other Medicine Technology:Metabasis Therapeutics Presents Results of Preclinical Studies for,MB07811, Its Novel Product Candidate for the Treatment of,Hyperlipidemia, at the Endocrine Society's Annual Meeting 2Metabasis Therapeutics Presents Results of Preclinical Studies for,MB07811, Its Novel Product Candidate for the Treatment of,Hyperlipidemia, at the Endocrine Society's Annual Meeting 3Metabasis Therapeutics Presents Results of Preclinical Studies for,MB07811, Its Novel Product Candidate for the Treatment of,Hyperlipidemia, at the Endocrine Society's Annual Meeting 4Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 2Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 3Newly Published Data from Large Study Support Cardiovascular Safety,of Avandia (Rosiglitazone Maleate) 4
Provide 1.5mm protection throughout. Six durable, attractive vinyl coverings are available. Lead glass window factory installed. Larger window available.
Swing-Arm™ Scatter Shield® provides lower extremity protection for personnel close to the tube. 24"Wx32"L lead shield swings 180 along table. Ideal for cardiac cath, special studies, electr
Front Protection with attached Belt Guard, Built-in Back Support; Buckle Closure
Surgical Drop-Off Apron
Medicine Products: